{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:17:18Z","timestamp":1783063038439,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Innovation and Entrepreneurship Training Program for College Students in Shaanxi Province","award":["S202511840087"],"award-info":[{"award-number":["S202511840087"]}]},{"name":"Key Research and Development Program of Shaanxi Province","award":["2021LL-JB-06"],"award-info":[{"award-number":["2021LL-JB-06"]}]},{"name":"Key Research and Development Program of Shaanxi Province","award":["2023-ZDLSF-40"],"award-info":[{"award-number":["2023-ZDLSF-40"]}]},{"name":"National Innovation Center for Advanced Medical Devices","award":["NMED2023AGP-014"],"award-info":[{"award-number":["NMED2023AGP-014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02291-1","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:24:31Z","timestamp":1778318671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transition from CSII to second-generation basal insulin analogues in hospitalized T2DM patients: a CGM-based study"],"prefix":"10.1186","volume":"26","author":[{"given":"Ruiqing","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiange","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuna","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanna","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"1","key":"2291_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ndt\/gfaf177","volume":"41","author":"BB Duncan","year":"2025","unstructured":"Duncan BB, Magliano DJ, Boyko EJ. IDF diabetes atlas 11th edition 2025: Global prevalence and projections for 2050[J]. Nephrol Dial Transpl. 2025;41(1):7\u20139.","journal-title":"Nephrol Dial Transpl"},{"key":"2291_CR2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024[J]. Diabetes Care. 2024, 47(Suppl 1): S179\u2013S218.","DOI":"10.2337\/dc24-S010"},{"issue":"Supplement1","key":"2291_CR3","first-page":"S158","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142024[J]. Diabetes Care. 2023;47(Supplement1):S158\u201378.","journal-title":"Diabetes Care"},{"issue":"9825","key":"2291_CR4","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","volume":"379","author":"AJ Garber","year":"2012","unstructured":"Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial[J]. Lancet. 2012;379(9825):1498\u2013507.","journal-title":"Lancet"},{"issue":"4","key":"2291_CR5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s00125-019-05080-9","volume":"63","author":"A Philis-Tsimikas","year":"2020","unstructured":"Philis-Tsimikas A, Klonoff DC, Khunti K, et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: The randomised, head-to-head CONCLUDE trial[J]. Diabetologia. 2020;63(4):698\u2013710.","journal-title":"Diabetologia"},{"key":"2291_CR6","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.2147\/DMSO.S468070","volume":"17","author":"W Qiang","year":"2024","unstructured":"Qiang W, Li M, Song S, et al. Initiation of Insulin Degludec in Chinese Hospitalized Patients with Type 2 Diabetes \u2013 A Single Center\u2019s Experience[J]. Diabetes Metab Syndr Obes. 2024;17:3535\u201346.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"2291_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1111\/dom.12531","volume":"17","author":"G Dailey","year":"2015","unstructured":"Dailey G, Lavernia F. A review of the safety and efficacy data for insulin glargine 300 units\/ml, a new formulation of insulin glargine[J]. Diabetes Obes Metab. 2015;17(12):1107\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2291_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40271-014-0068-x","volume":"7","author":"M Brod","year":"2014","unstructured":"Brod M, Alolga SL, Meneghini L. Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities[J]. Patient. 2014;7(4):437\u201350.","journal-title":"Patient"},{"key":"2291_CR9","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.2147\/DMSO.S386230","volume":"15","author":"M Chen","year":"2022","unstructured":"Chen M, Zhang P, Zhao Y, et al. Where to Initiate Basal Insulin Therapy: Inpatient or Outpatient Department? Real-World Observation in China[J]. Diabetes Metab Syndr Obes. 2022;15:3375\u201385.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"01","key":"2291_CR10","first-page":"21","volume":"14","author":"Expert Consensus on Short-term Insulin Intensive Therapy for Type 2 Diabetes Mellitus Writing Group","year":"2022","unstructured":"Expert Consensus on Short-term Insulin Intensive Therapy for Type 2 Diabetes Mellitus Writing Group. Expert consensus on short-term insulin intensive therapy for type 2 diabetes mellitus (2021 edition)[J]. Chin J Diabetes Mellitus. 2022;14(01):21\u201331.","journal-title":"Chin J Diabetes Mellitus"},{"issue":"Suppl 2","key":"2291_CR11","first-page":"S3","volume":"18","author":"D Rodbard","year":"2016","unstructured":"Rodbard D. Continuous Glucose Monitoring: A Review of Successes, Challenges, and Opportunities[J]. Diabetes Technol Ther. 2016;18(Suppl 2):S3\u201313.","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"2291_CR12","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society[J]. Diabetes Care. 2013;36(5):1384\u201395.","journal-title":"Diabetes Care"},{"issue":"12","key":"2291_CR13","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.2337\/dc14-0990","volume":"37","author":"H Yki-J\u00e4rvinen","year":"2014","unstructured":"Yki-J\u00e4rvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)[J]. Diabetes Care. 2014;37(12):3235\u201343.","journal-title":"Diabetes Care"},{"issue":"11","key":"2291_CR14","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","volume":"26","author":"MC Riddle","year":"2003","unstructured":"Riddle MC, Rosenstock J, Gerich J, et al. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients[J]. Diabetes Care. 2003;26(11):3080\u20136.","journal-title":"Diabetes Care"},{"key":"2291_CR15","doi-asserted-by":"publisher","first-page":"111986","DOI":"10.1016\/j.diabres.2024.111986","volume":"220","author":"G Cavalcante Lima Chagas","year":"2025","unstructured":"Cavalcante Lima Chagas G, Teixeira L, Clemente RC. Use of continuous glucose monitoring and point-of-care glucose testing in hospitalized patients with diabetes mellitus in non-intensive care unit settings: A systematic review and meta-analysis of randomized controlled trials[J]. Diabetes Res Clin Pract. 2025;220:111986.","journal-title":"Diabetes Res Clin Pract"},{"key":"2291_CR16","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes*. 7. Diabetes technology: Standards of care in diabetes\u20142026[J]. Diabetes Care. 2025, 49(Supplement_1): S150\u2013S165.","DOI":"10.2337\/dc26-S007"},{"issue":"08","key":"2291_CR17","first-page":"679","volume":"37","author":"Chinese Society of Endocrinology, Chinese Diabetes Society, Chinese Endocrinologist Association","year":"2021","unstructured":"Chinese Society of Endocrinology, Chinese Diabetes Society, Chinese Endocrinologist Association. China Insulin Pump Clinical Guideline(2021)[J]. Chin J Diabetes Mellitus. 2021;37(08):679\u2013701.","journal-title":"Chin J Diabetes Mellitus"},{"key":"2291_CR18","doi-asserted-by":"publisher","first-page":"1536292","DOI":"10.3389\/fendo.2025.1536292","volume":"16","author":"W Zhao","year":"2025","unstructured":"Zhao W, Zheng D, Shi X, et al. Clinical performance evaluation of the SiJoy GS1 continuous glucose monitor during oral glucose tolerance testing in healthy adults[J]. Front Endocrinol (Lausanne). 2025;16:1536292.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2291_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino T, Alexander CM, Amiel SA, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement[J]. Lancet Diabetes Endocrinol. 2023;11(1):42\u201357.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2291_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1089\/dia.2009.0015","volume":"11","author":"D Rodbard","year":"2009","unstructured":"Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring[J]. Diabetes Technol Ther. 2009;11(9):551\u201365.","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"2291_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/dia.2008.0107","volume":"11","author":"AL McCall","year":"2009","unstructured":"McCall AL, Cox DJ, Brodows R, et al. Reduced daily risk of glycemic variability: Comparison of exenatide with insulin glargine[J]. Diabetes Technol Ther. 2009;11(6):339\u201344.","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"2291_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1932296815599177","volume":"10","author":"C Fabris","year":"2015","unstructured":"Fabris C, Patek SD, Breton MD. Are Risk Indices Derived From CGM Interchangeable With SMBG-Based Indices?[J]. J Diabetes Sci Technol. 2015;10(1):50\u20139.","journal-title":"J Diabetes Sci Technol"},{"key":"2291_CR23","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences (2nd ed.)[M]. 1988."},{"issue":"10","key":"2291_CR24","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2337\/dc18-0559","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Cheng A, Ritzel R, et al. More similarities than differences testing insulin glargine 300 units\/mL versus insulin degludec 100 units\/mL in insulin-naive type 2 diabetes: The randomized head-to-head BRIGHT trial[J]. Diabetes Care. 2018;41(10):2147\u201354.","journal-title":"Diabetes Care"},{"key":"2291_CR25","doi-asserted-by":"publisher","first-page":"1285147","DOI":"10.3389\/fendo.2023.1285147","volume":"14","author":"EN Alhmoud","year":"2023","unstructured":"Alhmoud EN, Saad MO, Omar NE. Efficacy and safety of insulin glargine 300 units\/mL vs insulin degludec in patients with type 1 and type 2 diabetes: A systematic review and meta-analysis[J]. Front Endocrinol (Lausanne). 2023;14:1285147.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2291_CR26","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1517\/17425255.2015.1058779","volume":"11","author":"T Heise","year":"2015","unstructured":"Heise T, H\u00f6velmann U, Nosek L, et al. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine[J]. Expert Opin Drug Metab Toxicol. 2015;11(8):1193\u2013201.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 7","key":"2291_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.16645","volume":"27","author":"L Horv\u00e1th","year":"2025","unstructured":"Horv\u00e1th L, Novodvorsk\u00fd P, Haluz\u00edk M. Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist[J]. Diabetes Obes Metab. 2025;27(Suppl 7):42\u201354.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2291_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2337\/dc16-1957","volume":"40","author":"MI Maiorino","year":"2017","unstructured":"Maiorino MI, Chiodini P, Bellastella G, et al. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials[J]. Diabetes Care. 2017;40(4):614\u201324.","journal-title":"Diabetes Care"},{"issue":"1","key":"2291_CR29","doi-asserted-by":"publisher","first-page":"e3082","DOI":"10.1002\/dmrr.3082","volume":"35","author":"M Castellana","year":"2019","unstructured":"Castellana M, Cignarelli A, Brescia F, et al. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis[J]. Diabetes Metab Res Rev. 2019;35(1):e3082.","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"2291_CR30","doi-asserted-by":"publisher","first-page":"e002705","DOI":"10.1136\/bmjdrc-2021-002705","volume":"10","author":"T Idrees","year":"2022","unstructured":"Idrees T, Castro-Revoredo IA, Migdal AL, et al. Update on the management of diabetes in long-term care facilities[J]. BMJ Open Diabetes Res Care. 2022;10(4):e002705.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10","key":"2291_CR31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/jdi.14283","volume":"15","author":"H Umegaki","year":"2024","unstructured":"Umegaki H. Management of older adults with diabetes mellitus: Perspective from geriatric medicine[J]. J Diabetes Invest. 2024;15(10):1347\u201354.","journal-title":"J Diabetes Invest"},{"issue":"2","key":"2291_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/jdi.12884","volume":"10","author":"Y Kawaguchi","year":"2019","unstructured":"Kawaguchi Y, Sawa J, Sakuma N, et al. Efficacy and safety of insulin glargine 300 U\/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open-label, cross\u2010over study using continuous glucose monitoring profiles[J]. J Diabetes Investig. 2019;10(2):343\u201351.","journal-title":"J Diabetes Investig"},{"issue":"2","key":"2291_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/jdi.12894","volume":"10","author":"M Yamabe","year":"2019","unstructured":"Yamabe M, Kuroda M, Hirosawa Y, et al. Comparison of insulin glargine 300 U\/mL and insulin degludec using flash glucose monitoring: A randomized cross-over study[J]. J Diabetes Investig. 2019;10(2):352\u20137.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"2291_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.12782","volume":"19","author":"T Heise","year":"2017","unstructured":"Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes[J]. Diabetes Obes Metab. 2017;19(1):3\u201312.","journal-title":"Diabetes Obes Metab"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02291-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02291-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02291-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:40:16Z","timestamp":1783060816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02291-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2291"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02291-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8712412\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants comply with the ethical standards of the Declaration of Helsinki. This study was approved by the Institutional Review Board of the First Affiliated Hospital of Xi\u2019an Jiaotong University (No. XJTU1AF2023LSK-458). As this study was retrospective, the Institutional Review Board waived the requirement of obtaining the informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This manuscript has not been published elsewhere and has not been submitted to any other journal. All authors have approved the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}